SSY GROUP (02005) Obtains NMPA Approval for Levofloxacin Eye Drops Production

Stock News12-09

SSY GROUP (02005) announced that it has obtained the drug production registration approval from China's National Medical Products Administration (NMPA) for Levofloxacin Eye Drops (0.488% (5ml: 24.4mg)). Classified as a Category 4 chemical drug, the product is deemed to have passed the consistency evaluation. Levofloxacin Eye Drops are primarily used to treat blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomian gland inflammation, keratitis, and perioperative aseptic therapy in ophthalmology. This approval further enriches the company's portfolio of ophthalmic preparations.

The Board also announced that the Group has received NMPA approval for Compound Sodium Picosulfate Granules (10mg per sachet), classified as a Category 3 chemical drug and similarly deemed to have passed the consistency evaluation. The granules are mainly used for bowel cleansing preparation prior to colonoscopy or X-ray examination, as well as preoperative intestinal cleansing. As disclosed in the Company's December 4, 2025 announcement, SSY GROUP's sodium picosulfate active pharmaceutical ingredient has also been approved by the NMPA for use in marketed formulations.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1199237483?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-09 12:12","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1199237483","market":"sh","top_or_hot":-1,"title":"SSY GROUP (02005) Obtains NMPA Approval for Levofloxacin Eye Drops Production","media":"Stock News","content":"<p>SSY GROUP (02005) announced that it has obtained the drug production registration approval from China's National Medical Products Administration (NMPA) for Levofloxacin Eye Drops (0.488% (5ml: 24.4mg)). Classified as a Category 4 chemical drug, the product is deemed to have passed the consistency evaluation. Levofloxacin Eye Drops are primarily used to treat blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomian gland inflammation, keratitis, and perioperative aseptic therapy in ophthalmology. This approval further enriches the company's portfolio of ophthalmic preparations.</p>\n<p>The Board also announced that the Group has received NMPA approval for Compound Sodium Picosulfate Granules (10mg per sachet), classified as a Category 3 chemical drug and similarly deemed to have passed the consistency evaluation. The granules are mainly used for bowel cleansing preparation prior to colonoscopy or X-ray examination, as well as preoperative intestinal cleansing. As disclosed in the Company's December 4, 2025 announcement, SSY GROUP's sodium picosulfate active pharmaceutical ingredient has also been approved by the NMPA for use in marketed formulations.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>SSY GROUP (02005) Obtains NMPA Approval for Levofloxacin Eye Drops Production</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSSY GROUP (02005) Obtains NMPA Approval for Levofloxacin Eye Drops Production\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1036600163\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Stock News </p>\n<p class=\"h-time\">2025-12-09 12:12</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>SSY GROUP (02005) announced that it has obtained the drug production registration approval from China's National Medical Products Administration (NMPA) for Levofloxacin Eye Drops (0.488% (5ml: 24.4mg)). Classified as a Category 4 chemical drug, the product is deemed to have passed the consistency evaluation. Levofloxacin Eye Drops are primarily used to treat blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomian gland inflammation, keratitis, and perioperative aseptic therapy in ophthalmology. This approval further enriches the company's portfolio of ophthalmic preparations.</p>\n<p>The Board also announced that the Group has received NMPA approval for Compound Sodium Picosulfate Granules (10mg per sachet), classified as a Category 3 chemical drug and similarly deemed to have passed the consistency evaluation. The granules are mainly used for bowel cleansing preparation prior to colonoscopy or X-ray examination, as well as preoperative intestinal cleansing. As disclosed in the Company's December 4, 2025 announcement, SSY GROUP's sodium picosulfate active pharmaceutical ingredient has also been approved by the NMPA for use in marketed formulations.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK1191","symbol_name":"制药","start_time":0,"source_url":"","article_id":"1199237483","we_media_id":"1036600163","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1199237483","pubTimestamp":1765253537,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Stock News","introduction":"Global Stock News First-Time Broadcast","home_visible":1,"id":"1036600163","head_image":"https://community-static.tradeup.com/news/b3bf6d02ad1a6e9e7377eebbb162346a"},"summary":"SSY GROUP (02005) announced that it has obtained the drug production registration approval from China's National Medical Products Administration (NMPA) for Levofloxacin Eye Drops (0.488% (5ml:...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK1191":"制药","02005":"石四药集团","LU2460026573.USD":"abrdn SICAV I -  CHINA NEXT GENERATION \"A\" (USD) ACC"},"translate_title":"SSY集团(02005)左氧氟沙星滴眼液生产获NMPA批件","themeId":"","isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"02005":1},"content_text":"SSY GROUP (02005) announced that it has obtained the drug production registration approval from China's National Medical Products Administration (NMPA) for Levofloxacin Eye Drops (0.488% (5ml: 24.4mg)). Classified as a Category 4 chemical drug, the product is deemed to have passed the consistency evaluation. Levofloxacin Eye Drops are primarily used to treat blepharitis, hordeolum, dacryocystitis, conjunctivitis, meibomian gland inflammation, keratitis, and perioperative aseptic therapy in ophthalmology. This approval further enriches the company's portfolio of ophthalmic preparations.\nThe Board also announced that the Group has received NMPA approval for Compound Sodium Picosulfate Granules (10mg per sachet), classified as a Category 3 chemical drug and similarly deemed to have passed the consistency evaluation. The granules are mainly used for bowel cleansing preparation prior to colonoscopy or X-ray examination, as well as preoperative intestinal cleansing. As disclosed in the Company's December 4, 2025 announcement, SSY GROUP's sodium picosulfate active pharmaceutical ingredient has also been approved by the NMPA for use in marketed formulations.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.35.12","shortVersion":"4.35.12","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1199237483","isCrawlerRequest":true}